Format

Send to

Choose Destination
Oncologist. 2015 May;20(5):539-45. doi: 10.1634/theoncologist.2014-0291. Epub 2015 Apr 15.

[18F]-Fluorodeoxyglucose Positron Emission Tomography Standardized Uptake Value as a Predictor of Adjuvant Chemotherapy Benefits in Patients With Nasopharyngeal Carcinoma.

Author information

1
Department of Nuclear Medicine, Department of Biomedical Imaging and Radiological Science, School of Medicine, Department of Internal Medicine, Division of Hematology and Oncology, Molecular and Genomic Epidemiology Center, and Department of Otorhinolaryngology, China Medical University Hospital, Taichung, Taiwan, Republic of China.
2
Department of Nuclear Medicine, Department of Biomedical Imaging and Radiological Science, School of Medicine, Department of Internal Medicine, Division of Hematology and Oncology, Molecular and Genomic Epidemiology Center, and Department of Otorhinolaryngology, China Medical University Hospital, Taichung, Taiwan, Republic of China linchin13256@gmail.com.

Abstract

BACKGROUND:

The role of adjuvant chemotherapy for the treatment of nasopharyngeal carcinoma (NPC) is controversial, and the identification of adequate predictive factors is warranted. Therefore, we aimed to investigate whether the mean standardized uptake value (SUV) measured on [(18)F]-fluorodeoxyglucose (FDG) positron emission tomography (PET) could predict the survival benefits for NPC patients that receive adjuvant chemotherapy.

MATERIALS AND METHODS:

The data for 174 NPC patients who underwent PET/computed tomography before chemoradiation between January 2004 and January 2012 were reviewed. The SUV75% was recorded for primary tumors. All patients received intensity-modulated radiotherapy and cisplatin-based chemotherapy. Adjuvant chemotherapy consisted of 3 cycles of 75 mg/m(2) cisplatin and 1,000 mg/m(2) fluorouracil for 4 days.

RESULTS:

The optimal cutoff value was 8.35 for SUV75%, with 112 (64.4%) patients having lower SUV75% and 62 (35.6%) having higher SUV75%. Patients with lower SUV75% had significantly better 5-year overall survival (OS) and distant metastasis-free survival. Multivariate analysis revealed that tumor stage, SUV75%, and adjuvant chemotherapy were significant prognostic factors for OS. Patients with higher SUV75% had significantly higher 5-year OS rates with adjuvant chemotherapy than without adjuvant chemotherapy (84.3% vs. 32.4%, respectively; p < .001). However, in the lower SUV75% group, no differences in 5-year OS were observed between patients who received and those who did not receive adjuvant chemotherapy (92.4% vs. 93.3%, respectively; p = .682).

CONCLUSION:

The SUV75% on FDG PET for primary tumors could successfully identify NPC patients who may benefit from adjuvant chemotherapy.

KEYWORDS:

Adjuvant; Chemotherapy; Nasopharyngeal neoplasms; Positron emission tomography; Radiotherapy

PMID:
25876992
PMCID:
PMC4425380
DOI:
10.1634/theoncologist.2014-0291
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center